RESUMEN
Ibrutinib, an antineoplastic agent tackling chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia, falls under the category of BCS class II drugs, characterized by a puzzling combination of low solubility and high permeability. Its oral bioavailability remains a perplexing challenge, merely reaching 2.9 % due to formidable first-pass metabolism hurdles. In a bid to surmount this obstacle, researchers embarked on a journey to develop ibrutinib-loaded NLCs (Nanostructured Lipid Carriers) using a methodology steeped in complexity: a Design of Experiments (DoE)-based hot melted ultrasonication approach. Despite a plethora of methods for analyzing ibrutinib in various matrices, the absence of a spectrofluorimetric method for assessing it in rat plasma added to the enigma. Thus emerged a spectrofluorimetric method, embodying principles of white analytical chemistry and analytical quality by design, employing a Placket-Burman design for initial method exploration and a central composite design for subsequent refinement. This method underwent rigorous validation in accordance with ICH guidelines, paving the way for its application in scrutinizing the in-vivo pharmacokinetics of ibrutinib-loaded NLCs, juxtaposed against commercially available formulations. Surprisingly, the optimized NLCs exhibited a striking 1.82-fold boost in oral bioavailability, shedding light on their potential efficacy. The environmental impact of this method was scrutinized using analytical greenness tools, affirming its eco-friendly attributes. In essence, the culmination of these efforts has not only propelled advancements in drug bioavailability but also heralded the dawn of a streamlined and environmentally conscious analytical paradigm.
Asunto(s)
Adenina , Lípidos , Piperidinas , Pirimidinas , Espectrometría de Fluorescencia , Animales , Adenina/análogos & derivados , Adenina/farmacocinética , Adenina/química , Adenina/sangre , Piperidinas/farmacocinética , Piperidinas/química , Piperidinas/sangre , Lípidos/química , Masculino , Espectrometría de Fluorescencia/métodos , Ratas , Pirimidinas/farmacocinética , Pirimidinas/química , Pirimidinas/sangre , Portadores de Fármacos/química , Nanoestructuras/química , Pirazoles/farmacocinética , Pirazoles/química , Pirazoles/sangre , Pirazoles/administración & dosificación , Reproducibilidad de los Resultados , Ratas WistarRESUMEN
BACKGROUND AND OBJECTIVE: Within the UNIVERSAL project (RIA2019PD-2882) we aim to develop a paediatric dolutegravir (DTG)/emtricitabine (FTC or F)/tenofovir alafenamide (TAF) fixed-dose combination. To inform dosing of this study, we undertook a relative bioavailability (RBA) study in healthy volunteers to investigate a potential pharmacokinetic effect when paediatric formulations of DTG and F/TAF are taken together. METHODS: Participants received all of the following treatments as paediatric formulations in randomised order: a single dose of 180/22.5 mg F/TAF; a single dose of 30 mg DTG; a single dose of 180/22.5 mg F/TAF plus 30 mg DTG. Blood concentrations of DTG, FTC, TAF, and tenofovir (TFV) were measured over 48 h post-dose. If the 90% confidence intervals (CIs) of the geometric least squares mean (GLSM) ratios of area under the curve (AUC) and maximum concentration (Cmax) of each compound were within 0.70-1.43, we considered this as no clinically relevant PK interaction. RESULTS: A total of 15 healthy volunteers were included. We did not observe a clinically relevant PK interaction between the paediatric DTG and F/TAF formulations for the compounds DTG, FTC, and TFV. For TAF, the lower boundaries of the 90% CIs of the GLSM ratios of the AUC0-∞ and Cmax fell outside our acceptance criteria of 0.70-1.43. CONCLUSIONS: Although TAF AUC and Cmax 90% CIs fell outside the pre-defined criteria (0.62-1.11 and 0.65-1.01, respectively), no consistent effect on TAF PK was observed, likely due to high inter-subject variability. Moreover, there are several reasons to rely on TFV exposure as being more clinically relevant than TAF exposure. Therefore, we found no clinically relevant interactions in this study.
Asunto(s)
Alanina , Disponibilidad Biológica , Emtricitabina , Voluntarios Sanos , Compuestos Heterocíclicos con 3 Anillos , Oxazinas , Piperazinas , Piridonas , Comprimidos , Tenofovir , Humanos , Piridonas/farmacocinética , Compuestos Heterocíclicos con 3 Anillos/farmacocinética , Compuestos Heterocíclicos con 3 Anillos/administración & dosificación , Compuestos Heterocíclicos con 3 Anillos/sangre , Tenofovir/farmacocinética , Tenofovir/administración & dosificación , Tenofovir/análogos & derivados , Masculino , Emtricitabina/farmacocinética , Emtricitabina/administración & dosificación , Piperazinas/farmacocinética , Femenino , Adulto , Oxazinas/farmacocinética , Oxazinas/administración & dosificación , Alanina/farmacocinética , Alanina/administración & dosificación , Combinación de Medicamentos , Adulto Joven , Adenina/análogos & derivados , Adenina/farmacocinética , Adenina/administración & dosificación , Adenina/sangre , Fármacos Anti-VIH/farmacocinética , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/sangre , Área Bajo la Curva , Persona de Mediana Edad , Adolescente , Estudios CruzadosRESUMEN
OBJECTIVES: We measured the intracellular concentrations of tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) in dried blood spots (DBS) for pre-exposure prophylaxis (PrEP) adherence using sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS). METHODS: A total of 191 DBS were obtained from 85 participants who were receiving tenofovir disoproxil fumarate (TDF; 300 mg) and emtricitabine (FTC; 200 mg) as PrEP at the Sexual Health Clinic, National Center for Global Health and Medicine, Tokyo, Japan. DBS punch (3 mm) added to 25 µL of 50% methanol and 400 µL of internal standard solution was used for solid phase extraction. Chromatographic separation was achieved on an Atlantis Premier BEH C18 AX Column (50 mm × 2.1 mm i.d.; particle size 1.7 µm) using gradient elution (flow rate: 0.6 mL/min); injection volume: 7 µL and run time: 5.5 min. Calibration curves for the two drugs were linear in the range 0.05-12.5 ng/punch. RESULTS: We determined the intracellular TFV-DP and FTC-TP concentrations in 191 DBS obtained from 85 patients administered with TDF and FTC as PrEP. The analytical performance data (calibration curve and QC samples) for all the analytical runs met the acceptance criteria. Intracellular concentrations of TFV-DP and FTC-TP in the DBS remained stable for at least 24 h after oral administration. CONCLUSIONS: A multiplex LC-MS/MS method was successfully developed for DBS, which can be useful for monitoring the levels of TFV-DP and FTC-TP in individuals receiving PrEP.
Asunto(s)
Fármacos Anti-VIH , Pruebas con Sangre Seca , Emtricitabina , Infecciones por VIH , Profilaxis Pre-Exposición , Espectrometría de Masas en Tándem , Tenofovir , Humanos , Emtricitabina/farmacocinética , Emtricitabina/administración & dosificación , Emtricitabina/sangre , Profilaxis Pre-Exposición/métodos , Infecciones por VIH/prevención & control , Pruebas con Sangre Seca/métodos , Espectrometría de Masas en Tándem/métodos , Masculino , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/farmacocinética , Fármacos Anti-VIH/administración & dosificación , Femenino , Adulto , Cromatografía Liquida/métodos , Persona de Mediana Edad , Tenofovir/sangre , Tenofovir/farmacocinética , Tenofovir/administración & dosificación , Adenina/análogos & derivados , Adenina/administración & dosificación , Adenina/farmacocinética , Adenina/sangre , Adenina/uso terapéutico , Cumplimiento de la Medicación , Organofosfatos/sangre , Organofosfatos/farmacocinética , Organofosfatos/administración & dosificación , Organofosfatos/análisis , Polifosfatos/análisis , Polifosfatos/sangreRESUMEN
Organic anion transporters 1 (OAT1) and OAT3 are responsible for transporting adefovir (ADV) into renal tubular epithelial cells. Our previous research found that ADV accumulated in the renal interstitium and caused renal interstitial fibrosis when Oat1/3 were inhibited by OATs inhibitor probenecid for long-term. Mast cells (MCs) in the interstitial space are considered to be key drivers of renal fibrosis. The current work investigated the effect of ADV on MCs in vitro and during the development of interstitial fibrosis in rats. Results indicate that ADV triggers chymase release from cultured RBL-2H3 mast cells in a time-and concentration-dependent manner. Angiotensin II (Ang II) in renal interstitium is generated mainly by chymase, renin and other products released from MCs, and has a direct effect on fibrosis through the angiotensin receptor. The concentrations of Ang II and fibrosis was significantly increased after administration of ADV alone or with probenecid for 4 weeks. The MCs membrane stabilizer sodium cromoglycate (SCG) and the angiotensin receptor antagonist Valsartan (VAL) could ameliorate ADV-induced nephrotoxicity. Additionally, SCG or VAL could reduce the accumulation of ADV in the renal interstitium by upregulating the expression of Oat1/3 and multidrug resistance-associated protein 4. Therefore, ADV accumulation in the renal interstitium could promote the degranulation of interstitial MCs and drive the development of renal fibrosis. SCG or VAL could ameliorate ADV-associated fibrosis by decreasing degranulation of MCs and accelerating renal clearance of ADV.
Asunto(s)
Adenina/análogos & derivados , Adenina/toxicidad , Degranulación de la Célula/efectos de los fármacos , Fibrosis/inducido químicamente , Enfermedades Renales/inducido químicamente , Mastocitos/efectos de los fármacos , Organofosfonatos/toxicidad , Adenina/sangre , Animales , Modelos Animales de Enfermedad , Fibrosis/fisiopatología , Humanos , Enfermedades Renales/fisiopatología , Túbulos Renales/efectos de los fármacos , Masculino , Organofosfonatos/sangre , RatasRESUMEN
BACKGROUND: Pre-exposure prophylaxis (PrEP) is highly effective and an important prevention tool for African adolescent girls and young women (AGYW), but adherence and persistence are challenging. PrEP adherence support strategies for African AGYW were studied in an implementation study. METHODS AND FINDINGS: HIV Prevention Trials Network (HPTN) 082 was conducted in Cape Town, Johannesburg (South Africa) and Harare (Zimbabwe) from October 2016 to October 2018 to evaluate PrEP uptake, persistence, and the effect of drug level feedback on adherence. Sexually active HIV-negative women ages 16-25 were offered PrEP and followed for 12 months; women who accepted PrEP were randomized to standard adherence support (counseling, 2-way SMS, and adherence clubs) or enhanced adherence support with adherence feedback from intracellular tenofovir-diphosphate (TFV-DP) levels in dried blood spots (DBS). PrEP uptake, persistence through 12 months (no PrEP hold or missed visits), and adherence were assessed. The primary outcome was high adherence (TFV-DP ≥700 fmol/punch) at 6 months, compared by study arm. Of 451 women enrolled, median age was 21 years, and 39% had curable sexually transmitted infections (STIs). Most (95%) started PrEP, of whom 55% had uninterrupted PrEP refills through 12 months. Of those with DBS, 84% had detectable TFV-DP levels at month 3, 57% at month 6, and 31% at month 12. At 6 months, 36/179 (21%) of AGYW in the enhanced arm had high adherence and 40/184 (22%) in the standard adherence support arm (adjusted odds ratio [OR] of 0.92; 95% confidence interval [CI] 0.55, 1.34; p = 0.76). Four women acquired HIV (incidence 1.0/100 person-years), with low or undetectable TFV-DP levels at or prior to seroconversion, and none of whom had tenofovir or emtricitabine resistance mutations. The study had limited power to detect a modest effect of drug level feedback on adherence, and there was limited awareness of PrEP at the time the study was conducted. CONCLUSIONS: In this study, PrEP initiation was high, over half of study participants persisted with PrEP through month 12, and the majority of young African women had detectable TFV-DP levels through month 6 with one-fifth having high adherence. Drug level feedback in the first 3 months of PrEP use did not increase the proportion with high adherence at month 6. HIV incidence was 1% in this cohort with 39% prevalence of curable STIs and moderate PrEP adherence. Strategies to support PrEP use and less adherence-dependent formulations are needed for this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT02732730.
Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/uso terapéutico , Monitoreo de Drogas , Retroalimentación Psicológica , Infecciones por VIH/prevención & control , Cumplimiento de la Medicación , Organofosfatos/uso terapéutico , Profilaxis Pre-Exposición , Adenina/efectos adversos , Adenina/sangre , Adenina/uso terapéutico , Adolescente , Adulto , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/sangre , Consejo , Pruebas con Sangre Seca , Femenino , Infecciones por VIH/diagnóstico , Infecciones por VIH/transmisión , Infecciones por VIH/virología , Conocimientos, Actitudes y Práctica en Salud , Humanos , Organofosfatos/efectos adversos , Organofosfatos/sangre , Factores Sexuales , Sudáfrica , Envío de Mensajes de Texto , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven , ZimbabweRESUMEN
Recently, the use of antiretroviral drug tenofovir disoproxil fumarate (TDF) is increased, thanks to the new co-formulation with doravirine, the availability of booster-free regimens, and its advantageous lipid-lowering effect. The aim of our study was to identify genetic markers that contribute to assess the risk of TDF-related renal toxicity. We have retrospectively investigated, in 179 HIV positive patients treated with TDF, the association between the main variants in ABCC2, ABCC4, and ABCC10 genes and four safety endpoints, three clinically relevant as renal outcomes and a higher tenofovir plasma concentration. In patients with an annual eGFR decline >5 mL/min/1.73 m2 a difference in genotype frequencies was observed for ABCC10 c.1875 + 526 G>A (3 subjects AA vs. 44 GG + GA, p = 0.045). In patients with an eGFR decrement >25%, plus a decline in GFR category and TDF discontinuation, a difference was observed for ABCC4 c.*38T>G (35 subjects TG + GG vs. 18 TT, p = 0.052). At univariate analysis OR was 1.39 [(95% CI 1.00-1.96) p = 0.054] and at multivariate analysis OR was 1.49 [(95% CI 1.00-2.22) p = 0.049]. The stronger associations were found between the tenofovir accumulation and ABCC4 c.*38T>G and c.3348G>A: the percentage of these patients was higher in the TG + GG (p = 0.011) and in the AA (p = 0.004) genotype, respectively. The logistic regression analysis confirmed these significant relationships. No significant association was observed in patients with eGFR < 60 mL/min/1.73m2 and with the studied ABCC2 polymorphisms. Our results show a major role for a combined determination of ABCC4/ABCC10 variants as an indicator of tenofovir toxicity in the clinical practice.
Asunto(s)
Lesión Renal Aguda/inducido químicamente , Adenina/análogos & derivados , Fármacos Anti-VIH/toxicidad , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/genética , Ácidos Fosforosos/toxicidad , Polimorfismo de Nucleótido Simple/genética , Lesión Renal Aguda/genética , Adenina/sangre , Adenina/toxicidad , Adulto , Fármacos Anti-VIH/sangre , Femenino , Marcadores Genéticos/genética , Técnicas de Genotipaje , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Proteína 2 Asociada a Resistencia a Múltiples Medicamentos/genética , Ácidos Fosforosos/sangre , Estudios RetrospectivosRESUMEN
Recent studies have shown that therapeutic drug monitoring of tyrosine kinase inhibitors (TKIs) could improve treatment efficacy and safety. A simple analytical method using high-performance LC/electrospray ionization-tandem mass spectrometry has been developed and validated for simultaneous quantification of BCR-ABL and Bruton's TKIs used for chronic leukemia (imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib) in human plasma. Although these structures and physical properties are similar, owing to their different linear ranges, simultaneously determining the plasma levels of these five TKIs by applying optimal MS parameters remains difficult. A quantitative range exceeding 60,000-fold was required, and the linear dynamic ranges of imatinib, bosutinib, and nilotinib were limited because of the presence of a saturated detection signal. In this study, we applied the in-source collision-induced dissociation technique to control the ion amounts in mass spectrometry. This new method allowed rapid determination within 5 min with simple pretreatment. The method was validated according to the US Food and Drug Administration guidelines. Moreover, all samples of patients with chronic leukemia were successfully measured and their values were within the linear range of measurement. Therefore, our high-throughput analytical system is useful to measure the plasma concentrations of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in clinical practice.
Asunto(s)
Cromatografía Liquida/métodos , Monitoreo de Drogas/métodos , Inhibidores de Proteínas Quinasas/sangre , Espectrometría de Masa por Ionización de Electrospray/métodos , Adenina/análogos & derivados , Adenina/sangre , Adenina/uso terapéutico , Compuestos de Anilina/sangre , Compuestos de Anilina/uso terapéutico , Dasatinib/sangre , Dasatinib/uso terapéutico , Femenino , Ensayos Analíticos de Alto Rendimiento , Humanos , Mesilato de Imatinib/sangre , Mesilato de Imatinib/uso terapéutico , Leucemia/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Nitrilos/sangre , Nitrilos/uso terapéutico , Piperidinas/sangre , Piperidinas/uso terapéutico , Inhibidores de Proteínas Quinasas/uso terapéutico , Pirimidinas/sangre , Pirimidinas/uso terapéutico , Quinolinas/sangre , Quinolinas/uso terapéutico , Espectrometría de Masas en Tándem/métodosRESUMEN
A bimetallic nanoparticles modified halloysite nanotubes (HNTs) hybrid was prepared by embedding AgNPs and modifying AuNPs on the inner or outer wall of dopamine-modified HNTs (DHNTs) in sequence. The resulting bimetallic AgNPs@DHNTs-AuNPs hybrid as surface-enhanced Raman scattering (SERS) substrate exhibited improved enhancement ability over monometallic AgNPs@DHNTs, and DHNTs-AuNPs substrates, with intensity ratios of about 48:1:9 (crystal violet) and 11:1:2 (p-phenylenediamine). The giant SERS effect of AgNPs@DHNTs-AuNPs substrate is probably attributed to the synergetic enhancement of the electromagnetic field (Au/Ag), optical plasmon force, molecular enrichment (HNTs), and charge transfer (NPs-dopamine-molecules). The sensitive and reproductive AgNPs@DHNTs-AuNPs substrate was applied for SERS determination of adenine with a linear range of 0.010-0.50 mg·L-1 and a detection limit of 2.2 µg·L-1. The SERS method enables the rapid determination of adenine in fish, chicken kidney and heart, and serum samples, with recoveries of 83.5-121.6% and relative standard deviations of 2.5-7.9%. The SERS substrate has high value for rapid analysis of food and biomarker determinations. Schematic illustration of the preparation of AgNPs@HNTs-AuNPs for SERS analysis of adenine in complex sample.
Asunto(s)
Adenina/sangre , Nanopartículas del Metal/química , Nanotubos/química , Animales , Biomarcadores/sangre , Pollos , Arcilla/química , Dopamina/química , Peces , Oro/química , Riñón/química , Límite de Detección , Miocardio/química , Reproducibilidad de los Resultados , Plata/química , Espectrometría Raman/métodosRESUMEN
INTRODUCTION: HIV incidence remains high among African adolescent girls and young women (AGYW), who would benefit from pre-exposure prophylaxis (PrEP). Strategies to increase PrEP adherence and persistence need to be evaluated in African AGY, including incentives conditional on high adherence. METHODS: The 3Ps for Prevention Study was a 12-month prospective cohort of 200 women ages 16 to 25 initiating PrEP in South Africa from 2017 to 2018. Participants received retrospective feedback about drug levels at Months 1, 2 and 3; half was randomized to receive a 200 Rand shopping voucher ($13 US) at Months 2, 3 and 4, conditioned on high intracellular tenofovir diphosphate (TFV-DP) levels in dried blood spots (≥500 fmol/punch at Month 1, ≥700 fmol/punch at Months 2 and 3). The primary analysis was intention-to-treat, comparing the proportion with high PrEP adherence (≥700 fmol/punch) at Month 3 by randomized group, based on 100% efficacy among men who have sex with men. RESULTS: Median age of the 200 women was 19 years (interquartile range [IQR] 17, 21); 86% had a primary sexual partner. At Month 3, the mean TFV-DP level was 822 fmol/punch (SD 522) in the incentive group and 689 fmol/punch (SD 546) in the control group (p = 0.11). Forty-five (56%) of 85 women in the incentive group and 35 (41%) of 85 women in the control group had TFV-DP levels ≥700 fmol/punch (RR 1.35; 95% CI 0.98, 1.86; p = 0.067), which declined to 8% and 5% in the incentive and control groups at Month 12 (no significant difference by arm). 44% refilled PrEP without gaps, 14% had a gap of ≥3 weeks in coverage subsequently restarted PrEP and 54% accepted at the final dispensing visit at Month 9. No new HIV infections were observed after PrEP initiation. CONCLUSIONS: Among South African AGYW initiating PrEP, drug levels indicated high PrEP adherence in almost half of women at Month 3, with a non-statistically significant higher proportion with high adherence among those in the incentive group. Over half persisted with the 12-month PrEP programme although high adherence declined after Month 3. Strategies to support PrEP adherence and persistence and longer-acting PrEP formulations are needed.
Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/sangre , Infecciones por VIH/prevención & control , Cumplimiento de la Medicación , Motivación , Organofosfatos/sangre , Profilaxis Pre-Exposición , Adenina/sangre , Adenina/uso terapéutico , Adolescente , Adulto , Fármacos Anti-VIH/uso terapéutico , Población Negra , Femenino , Humanos , Incidencia , Organofosfatos/uso terapéutico , Sudáfrica , Adulto JovenRESUMEN
In this work, Fe3O4/N co-doped hollow carbon spheres (Fe3O4@NHCS) as a promising electrocatalysis material had been prepared through carbonizing covalent organic frameworks and ferric irons. The morphology, structure, composition and electrocatalytic performance of Fe3O4@NHCS were characterized by various techniques. The electrode modified with Fe3O4@NHCS (Fe3O4@NHCS/GCE) exhibited excellent electrocatalytic activity for the oxidation of dopamine, uric acid, guanine and adenine. Simultaneous determination of these biomolecules was successfully achieved with Fe3O4@NHCS/GCE. Under the optimum conditions, the linear ranges for the determination of dopamine, uric acid, guanine and adenine were 0.01-40, 0.10-40, 0.50-30 and 0.50-40 µmol/L with the correlation coefficients of 0.9905, 0.9906, 0.9919 and 0.9908, respectively. The detection limits were 6.3, 36.1, 143.2 and 123.5 nmol/L for dopamine, uric acid, guanine and adenine, respectively (S/N = 3). In addition, the modified electrode was also applied to the simultaneous determination of these biomolecules in human serum samples and the recovery were varied from 97.6% to 104.2%. The results demonstrated that the Fe3O4@NHCS modified electrode had the characteristics of high sensitivity, good selectivity and reliability.
Asunto(s)
Adenina/sangre , Dopamina/sangre , Guanina/sangre , Estructuras Metalorgánicas/química , Ácido Úrico/sangre , Técnicas Biosensibles , Carbono/química , Técnicas Electroquímicas , Electrodos , Compuestos Férricos/química , Humanos , Nanosferas/química , Tamaño de la Partícula , Propiedades de SuperficieRESUMEN
Tenofovir alafenamide (TAF) is a potent prodrug of tenofovir (TFV) for HIV prophylaxis, and HIV and HBV treatment. Compared to oral daily doses, transdermal administration of TAF may be more advantageous for long-term adherence by offering sustained drug delivery and reduced dosing frequency. Here, we described the plasma pharmacokinetics (PK) of an optimized once-weekly suspension transdermal delivery system (TDS) for TAF (96 mg/25 cm2 of TDS) in female hairless rats. Over the study period, the TAF TDS delivered an overall low level of TAF (median: 1.43 [0.02-3.28] ng/mL) and a sustained level of the stable metabolite and parent drug, TFV. Relative to the projected exposure corresponding to six-day oral daily doses, a comparable TAF exposure but a substantially lower TFV exposure was resulted from the TAF TDS, suggesting a lower risk of TFV-associated adverse effects. TAF, TFV, and phosphorylated TFVs (TFV-monophosphate and diphosphate) were found distributed in vaginal tissue, the portal of entry for HIV during male-to-female sexual transmission. Skin adhesion and tolerance were acceptable given the animal model used. PK evaluation of the TAF TDS in hairless rats demonstrates the proof of concept that transdermal delivery can be an alternative route for a sustained, once-weekly systemic delivery of TAF.
Asunto(s)
Adenina/análogos & derivados , Antivirales/administración & dosificación , Antivirales/farmacocinética , Adenina/administración & dosificación , Adenina/sangre , Adenina/farmacocinética , Adenina/toxicidad , Administración Cutánea , Administración Oral , Alanina , Animales , Antivirales/sangre , Antivirales/toxicidad , Preparaciones de Acción Retardada , Esquema de Medicación , Composición de Medicamentos , Femenino , Inyecciones Intravenosas , Prueba de Estudio Conceptual , Ratas sin Pelo , Tenofovir/análogos & derivados , Distribución Tisular , Parche Transdérmico , Vagina/metabolismoRESUMEN
Inadequate adherence to chronic medications is a far-reaching problem with financial and human health consequences. By a wide margin, non-adherence is the leading cause of therapeutic failures of HIV pre-exposure chemoprophylaxis (PrEP) and antiretroviral therapy (ART). It has been proven that HIV infection can be prevented by daily dosing of emtricitabine and tenofovir disoproxil fumarate. Measurement of intracellular tenofovir diphosphate in red blood cells has been established as an effective way to assess cumulative adherence, however, the LC-MS-based analytical method developed for the purpose is both complicated and expensive. Here, we report a simple method for adherence monitoring based on direct MS quantification of intracellular tenofovir diphosphate in human whole blood. The method requires only microliters of whole blood, employs special membranes to perform plasma separation and concomitant desalting during blood collection, and uses nanoelectrospray on a triple quadrupole instrument. Quantitative performance in this proof-of-concept study includes RSDs of < 15% and successful analysis of a small number of patient samples with medium to high adherence levels. The results correlate with those of a validated LC-MS/MS method, and an R2 value of 0.9962 is achieved. This methodology has promise for extension to point-of-care testing using miniature mass spectrometers. Graphical abstract.
Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/sangre , Organofosfatos/sangre , Espectrometría de Masas en Tándem/métodos , Adenina/sangre , Adenina/normas , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/normas , Cromatografía Liquida/métodos , Humanos , Organofosfatos/normas , Prueba de Estudio Conceptual , Estándares de ReferenciaRESUMEN
We describe the in vitro and in vivo evaluation of a subcutaneous reservoir implant delivering tenofovir alafenamide hemifumarate (TAF) for the prevention of HIV infection. These long-acting reservoir implants were able to deliver antiretroviral drug for over 90 days in vitro and in vivo We evaluated the implants for implantation site histopathology and pharmacokinetics in plasma and tissues for up to 12 weeks in New Zealand White rabbit and rhesus macaque models. A dose-ranging study in rabbits demonstrated dose-dependent pharmacokinetics and local inflammation up to severe necrosis around the active implants. The matched placebos showed normal wound healing and fibrous tissue encapsulation of the implant. We designed a second implant with a lower release rate and flux of TAF and achieved a median cellular level of tenofovir diphosphate of 42 fmol per 106 rhesus macaque peripheral blood mononuclear cells at a TAF dose of 10 µg/kg/day. This dose and flux of TAF also resulted in adverse local inflammation and necrosis near the implant in rhesus macaques. The level of inflammation in the primates was markedly lower in the placebo group than in the active-implant group. The histological inflammatory response to the TAF implant at 4 and 12 weeks in primates was graded as a severe reaction. Thus, while we were able to achieve a sustained target dose, we observed an unacceptable inflammatory response locally at the implant tissue interface.
Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/efectos adversos , Preparaciones de Acción Retardada , Implantes de Medicamentos/administración & dosificación , Necrosis/inducido químicamente , Poliuretanos/administración & dosificación , Adenina/efectos adversos , Adenina/sangre , Adenina/farmacocinética , Alanina , Animales , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/farmacocinética , Femenino , Fumaratos/química , Infecciones por VIH/prevención & control , Humanos , Inflamación , Macaca mulatta , Masculino , Necrosis/patología , Conejos , Tejido Subcutáneo/cirugía , Tenofovir/análogos & derivadosRESUMEN
BACKGROUND: Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a strong predictor of viral suppression in persons living with HIV (PLWH). Its association with antiretroviral therapy (ART) resistance remains unknown. METHODS: Blood was collected in PLWH receiving TDF-containing ART enrolled in a 48-week study. Tenofovir diphosphate/emtricitabine triphosphate (FTC-TP) were quantified from the same sample as HIV viral load (VL) in PLWH who developed resistance within ≤12 months. RESULTS: The study enrolled 807 participants, of whom 10 had new resistance-conferring mutations. Among these, median (interquartile range) TFV-DP and HIV VL were 956 (407-1510) fmol/punch and 9840 (513-68,200) copies/mL, respectively. Five had quantifiable FTC-TP in DBS. Based on previously published data, a TFV-DP concentration of 956 fmol/punch would have an adjusted odds of virologic suppression of 32.8 versus TFV-DP <350 fmol/punch, making viremia of â¼10,000 copies/mL an unexpected outcome. CONCLUSION: Moderately high TFV-DP in DBS (700-1249 fmol/punch) in PLWH with high viremia suggest that antiretroviral drug resistance might be present.
Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/sangre , Pruebas con Sangre Seca , Farmacorresistencia Viral , Infecciones por VIH/tratamiento farmacológico , Organofosfatos/sangre , Carga Viral/efectos de los fármacos , Viremia/tratamiento farmacológico , Adenina/sangre , Adenina/uso terapéutico , Adulto , Fármacos Anti-VIH/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Organofosfatos/uso terapéutico , Estudios Prospectivos , Respuesta Virológica SostenidaRESUMEN
As a tool to be used in transporter-mediated drug-drug interaction studies, a sensitive LC-MS/MS method for the simultaneous quantification of adefovir and pitavastatin in human plasma and adefovir in urine was developed and successfully validated. Plasma samples were processed by protein precipitation using methanol with a subsequent concentrating step. Urine samples were diluted using 0.1% formic acid. Separation was achieved on a Synergy Polar-RP reversed phase column (50â¯×â¯4.6â¯mm, 2.5⯵m) in gradient elution using a mobile phase composed of water and 0.1% formic acid and a mixture of methanol and acetonitrile (50:50, v/v) containing 0.1% formic acid at a flow rate of 1.0â¯mL/min. The linear range covered concentrations from 0.273 to 52.6â¯ng/mL for adefovir and from 0.539 to 104.2â¯ng/mL for pitavastatin in human plasma, respectively. The calibration curve for adefovir in urine ranged from 0.104 to 10.0⯵g/mL. The weighted linear regression (1/conc2) implied excellent linearity with correlation coefficients ≥0.999.
Asunto(s)
Adenina/análogos & derivados , Cromatografía Líquida de Alta Presión/métodos , Organofosfonatos/sangre , Organofosfonatos/orina , Quinolinas/sangre , Quinolinas/orina , Espectrometría de Masas en Tándem/métodos , Adenina/sangre , Adenina/farmacología , Adenina/orina , Humanos , Organofosfonatos/farmacología , Plasma/química , Quinolinas/farmacologíaRESUMEN
Guanine and adenine in blood samples can be detected by using an electrochemical sensor based on the use of manganese dioxide (MnO2) nanosheets and ionic liquid functionalized graphene (IL-GR) bound to a polydopamine (PDA) membrane. Both guanine and adenine undergo a redox reaction on the surface of the modified electrode. Cyclic voltammetry and differential pulse voltammetry were used to evaluate the electrochemical behavior of a glassy carbon electrode (GCE) modified with PDA/MnO2/IL-GR. The sensor allows for individual as well as simultaneous determination of guanine and adenine. The working voltage of differential pulse voltammetry at which data were acquired to establish the calibration plot: 0.6-1.2 V for guanine, 0.8-1.4 V for adenine, 0.4-1.4 V for mixture of guanine and adenine. A wide detection range (10-300 µM), low detection limits (guanine: 0.25 µM; adenine: 0.15 µM), selectivity and reproducibility are demonstrated. The modified GCE was successfully applied to the analysis of guanine and adenine in spiked fetal bovine serum and mouse whole blood samples. Graphical abstract An electrochemical sensor is presented for the determination of guanine (G) and adenine (A) based on MnO2 nanosheets, ionic liquid functionalized graphene (IL-graphene) and polydopamine membrane.
Asunto(s)
Adenina/sangre , Grafito/química , Guanina/sangre , Indoles/química , Líquidos Iónicos/química , Nanoestructuras/química , Polímeros/química , Animales , Bovinos , Técnicas Electroquímicas/instrumentación , Técnicas Electroquímicas/métodos , Electrodos , Límite de Detección , Compuestos de Manganeso/química , Membranas Artificiales , Ratones , Óxidos/química , Reproducibilidad de los ResultadosRESUMEN
Tenofovir alafenamide (TAF) is a newly developed prodrug of tenofovir (TFV). We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study. There were no significant differences in the alterations in the serum levels of HBs antigen (HBsAg) level between the ETV continuation and the TAF switching groups at 24 or 48 weeks. We also examined the effect of baseline HBsAg level on the decrease of HBsAg during the treatment; in the TAF switching group, the decrease of HBsAg level at 48 weeks was more significant in patients with low baseline HBsAg (<800 IU/mL) than those with high baseline HBsAg ( >800 IU/mL) (change of HBsAg; - 0.029 vs - 0.132 for high and low baseline HBsAg, respectively, P = .007). Also, the effect on renal function was found to be comparable between the TAF switch group and the ETV continuation group. In this study, switching from ETV to TAF may represent higher efficacy for a decrease of HBsAg than a continuation of ETV among the patients with low baseline HBsAg level.
Asunto(s)
Adenina/análogos & derivados , Antivirales/uso terapéutico , Guanina/análogos & derivados , Hepatitis B Crónica/tratamiento farmacológico , Adenina/sangre , Adenina/uso terapéutico , Adulto , Anciano , Alanina , Antivirales/sangre , Femenino , Guanina/sangre , Guanina/uso terapéutico , Antígenos de Superficie de la Hepatitis B/sangre , Humanos , Masculino , Persona de Mediana Edad , Tenofovir/análogos & derivadosRESUMEN
An electrochemical sensor for adefovir dipivoxil (ADV) detection was prepared by electropolymerization of o-phenylenediamine in the presence of ADV on a glassy carbon electrode modified with multi-walled carbon nanotubes and carbon nitride. The electrode was characterized by field emission scanning electron microscopy and differential pulse voltammetry. The performance was optimized by response surface methodology. The changes in differential pulse voltammetric peak currents of the redox probe, ferricyanide, were linear to ADV concentrations in the range from 0.1 to 9.9 µmol L-1, with the detection limit of 0.05 µmol L-1 (S/N = 3). The sensor was applied to the determination of ADV in drug formulations, human serum and urine samples. It is selective due to the use of an imprinted material, well reproducible, long-term stable, and regenerable. Graphical abstract By merging the unique properties of carbon nitride with intrinsic properties of MWCNTs, and molecularly imprinted polymers, a novel electrochemical sensor with selective binding sites was prepared for determination of adefovir dipivoxil in pharmaceutical and biological samples.
Asunto(s)
Adenina/análogos & derivados , Técnicas Electroquímicas/métodos , Nanocompuestos/química , Nanotubos de Carbono/química , Nitrilos/química , Organofosfonatos/análisis , Fenilendiaminas/química , Adenina/análisis , Adenina/sangre , Adenina/orina , Técnicas Electroquímicas/instrumentación , Electrodos , Humanos , Límite de Detección , Impresión Molecular , Organofosfonatos/sangre , Organofosfonatos/orina , Reproducibilidad de los ResultadosRESUMEN
The Partners Demonstration Project was a prospective, open-label, implementation science-driven study of preexposure prophylaxis (PrEP) among heterosexual HIV serodiscordant couples in Kenya and Uganda. Adherence data were collected using the Medication Event Monitoring System (MEMS), and time of sexual activity was collected using the mobile phone short message service (SMS). Two plasma samples were collected at a single study visit. We integrated adherence, pharmacokinetics, and SMS data using a population pharmacokinetic (PopPK) model to simulate tenofovir plasma concentrations from PrEP at the time of sexual activity. In the first stage of this analysis, we used data from the current study to update a prior PopPK model of tenofovir (TFV) developed with data from the Partners PrEP Study (a phase III clinical trial). The second stage involved simulating plasma concentrations at the time of sexual activity using empirical Bayes estimates (EBEs) derived from the final model. In addition, EBEs from a previously published parent metabolite model of TFV (MTN-001, an open-label 3-way crossover study in healthy women) was used to simulate tenofovir diphosphate (TFV-DP) concentrations. We estimated percent PrEP "coverage" as the number of reported sexual events during which simulated concentrations were above an a priori threshold concentrations associated with a high degree of protection from HIV infection: plasma TFV of >40 ng/ml and peripheral blood mononuclear cell (PBMC) TFV-DP concentration of >36 fmol/million cells. The levels of coverage were 72% for TFV and 81% for TFV-DP. These levels are consistent with a high degree of protection against HIV acquisition in this study of a pragmatic delivery model for antiretroviral-based HIV prevention.
Asunto(s)
Fármacos Anti-VIH/farmacocinética , Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/sangre , Infecciones por VIH/tratamiento farmacológico , VIH/efectos de los fármacos , Tenofovir/farmacocinética , Tenofovir/uso terapéutico , Adenina/análogos & derivados , Adenina/sangre , Adenina/farmacocinética , Adenina/uso terapéutico , Fármacos Anti-VIH/sangre , Teorema de Bayes , Estudios Cruzados , Femenino , Humanos , Kenia , Leucocitos Mononucleares/virología , Masculino , Organofosfatos/sangre , Organofosfatos/farmacocinética , Organofosfatos/uso terapéutico , Profilaxis Pre-Exposición/métodos , Estudios Prospectivos , Parejas Sexuales , Tenofovir/sangre , UgandaRESUMEN
BACKGROUND: Objective adherence metrics for tenofovir (TFV) disoproxil fumarate/emtricitabine (FTC)-based pre-exposure prophylaxis (PrEP) were critical for interpretation of efficacy in PrEP clinical trials, and there is increasing interest in using drug levels to tailor interventions for reengagement and adherence. Point-of-care immunoassays for TFV, which examine short-term adherence, are in development. However, the ability of poor short-term and long-term adherence to predict future PrEP nonretention is unknown. SETTING: Secondary data analysis of a large, prospective multi-site U.S. PrEP demonstration project. METHODS: An adjusted Cox-proportional hazards model examined the relationship of dried blood spot (DBS) levels of FTC-triphosphate (FTC-TP) or TFV-diphosphate (TFV-DP), measures of short-term and long-term PrEP adherence, respectively, with future study nonretention. RESULTS: Overall, 294 individuals (median age 33 years) contributed drug levels within the U.S. PrEP demonstration project. By the end of study, 27% were lost to follow-up, 25% had at least one undetectable FTC-TP level indicating poor short-term adherence, and 29% had a drug level indicating suboptimal long-term adherence (TFV-DP <700 fmol/punch). The strongest factor associated with future study nonretention using a binary drug-level cut-off was an undetectable DBS FTC-TP level (adjusted hazard ratio 6.3; 95% confidence interval 3.8 to 10.2). The suboptimal long-term adherence based on low DBS TFV-DP levels was also associated with nonretention (adjusted hazard ratio 4.3; 95% confidence interval: 2.4 to 7.6). CONCLUSIONS: Both short- and long-term metrics of PrEP adherence are strongly associated with future loss to follow-up in a U.S. demonstration project study. Short-term metrics of adherence, once available at the point-of-care, could be used to direct real-time tailored retention and adherence interventions.